3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
34
Neoplasms
8
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
HER2-positive Breast Cancer
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
Gemcitabine
7
Oxaliplatin
6
Cisplatin
5
durvalumab
3
130-nm albumin-bound paclitaxel
3
pembrolizumab
2
Leucovorin
2
Drug Therapy
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
sintilimab
1
pertuzumab
1
anlotinib
1
Trastuzumab
1
Taxes
1
Standard of Care
1
Platinum
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Long-Term Synaptic Depression
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
Commerce
1
Cholangiopancreatography, Endoscopic Retrograde
1
Biopsy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gallbladder Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled